NewGenIvf Group Limited
NewGenIvf Group Limited (NIVF) Stock Competitors & Peer Comparison
See (NIVF) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Plans Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NIVF | $0.84 | +0.00% | 20.5K | N/A | $4,195.34 | N/A |
| UNH | $289.93 | +0.00% | 262.8B | 21.95 | $13.22 | +3.01% |
| ANTM | $482.58 | +2.71% | 114.6B | 18.99 | $25.41 | +1.00% |
| CVS | $77.32 | +0.00% | 97.6B | 55.18 | $1.39 | +3.48% |
| ELV | $348.18 | +0.00% | 75.7B | 13.61 | $25.21 | +1.99% |
| CI | $285.92 | +0.00% | 74.9B | 12.64 | $22.18 | +2.16% |
| HUM | $190.50 | +0.00% | 22.8B | 17.76 | $10.69 | +1.86% |
| CNC | $43.68 | +0.00% | 21.3B | -3.15 | -$13.72 | N/A |
| MOH | $148.24 | +0.00% | 7.8B | 16.95 | $8.91 | N/A |
| ALHC | $20.84 | +0.00% | 4.1B | -187.27 | -$0.11 | N/A |
Stock Comparison
NIVF vs UNH Comparison February 2026
NIVF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NIVF stands at 20.5K. In comparison, UNH has a market cap of 262.8B. Regarding current trading prices, NIVF is priced at $0.84, while UNH trades at $289.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NIVF currently has a P/E ratio of N/A, whereas UNH's P/E ratio is 21.95. In terms of profitability, NIVF's ROE is +1.17%, compared to UNH's ROE of +0.13%. Regarding short-term risk, NIVF is more volatile compared to UNH. This indicates potentially higher risk in terms of short-term price fluctuations for NIVF.Check UNH's competition here
NIVF vs ANTM Comparison February 2026
NIVF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NIVF stands at 20.5K. In comparison, ANTM has a market cap of 114.6B. Regarding current trading prices, NIVF is priced at $0.84, while ANTM trades at $482.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NIVF currently has a P/E ratio of N/A, whereas ANTM's P/E ratio is 18.99. In terms of profitability, NIVF's ROE is +1.17%, compared to ANTM's ROE of +0.13%. Regarding short-term risk, NIVF is more volatile compared to ANTM. This indicates potentially higher risk in terms of short-term price fluctuations for NIVF.Check ANTM's competition here
NIVF vs CVS Comparison February 2026
NIVF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NIVF stands at 20.5K. In comparison, CVS has a market cap of 97.6B. Regarding current trading prices, NIVF is priced at $0.84, while CVS trades at $77.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NIVF currently has a P/E ratio of N/A, whereas CVS's P/E ratio is 55.18. In terms of profitability, NIVF's ROE is +1.17%, compared to CVS's ROE of +0.02%. Regarding short-term risk, NIVF is more volatile compared to CVS. This indicates potentially higher risk in terms of short-term price fluctuations for NIVF.Check CVS's competition here
NIVF vs ELV Comparison February 2026
NIVF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NIVF stands at 20.5K. In comparison, ELV has a market cap of 75.7B. Regarding current trading prices, NIVF is priced at $0.84, while ELV trades at $348.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NIVF currently has a P/E ratio of N/A, whereas ELV's P/E ratio is 13.61. In terms of profitability, NIVF's ROE is +1.17%, compared to ELV's ROE of +0.13%. Regarding short-term risk, NIVF is more volatile compared to ELV. This indicates potentially higher risk in terms of short-term price fluctuations for NIVF.Check ELV's competition here
NIVF vs CI Comparison February 2026
NIVF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NIVF stands at 20.5K. In comparison, CI has a market cap of 74.9B. Regarding current trading prices, NIVF is priced at $0.84, while CI trades at $285.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NIVF currently has a P/E ratio of N/A, whereas CI's P/E ratio is 12.64. In terms of profitability, NIVF's ROE is +1.17%, compared to CI's ROE of +0.15%. Regarding short-term risk, NIVF is more volatile compared to CI. This indicates potentially higher risk in terms of short-term price fluctuations for NIVF.Check CI's competition here
NIVF vs HUM Comparison February 2026
NIVF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NIVF stands at 20.5K. In comparison, HUM has a market cap of 22.8B. Regarding current trading prices, NIVF is priced at $0.84, while HUM trades at $190.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NIVF currently has a P/E ratio of N/A, whereas HUM's P/E ratio is 17.76. In terms of profitability, NIVF's ROE is +1.17%, compared to HUM's ROE of +0.07%. Regarding short-term risk, NIVF is more volatile compared to HUM. This indicates potentially higher risk in terms of short-term price fluctuations for NIVF.Check HUM's competition here
NIVF vs CNC Comparison February 2026
NIVF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NIVF stands at 20.5K. In comparison, CNC has a market cap of 21.3B. Regarding current trading prices, NIVF is priced at $0.84, while CNC trades at $43.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NIVF currently has a P/E ratio of N/A, whereas CNC's P/E ratio is -3.15. In terms of profitability, NIVF's ROE is +1.17%, compared to CNC's ROE of -0.28%. Regarding short-term risk, NIVF is more volatile compared to CNC. This indicates potentially higher risk in terms of short-term price fluctuations for NIVF.Check CNC's competition here
NIVF vs MOH Comparison February 2026
NIVF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NIVF stands at 20.5K. In comparison, MOH has a market cap of 7.8B. Regarding current trading prices, NIVF is priced at $0.84, while MOH trades at $148.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NIVF currently has a P/E ratio of N/A, whereas MOH's P/E ratio is 16.95. In terms of profitability, NIVF's ROE is +1.17%, compared to MOH's ROE of +0.11%. Regarding short-term risk, NIVF is more volatile compared to MOH. This indicates potentially higher risk in terms of short-term price fluctuations for NIVF.Check MOH's competition here
NIVF vs ALHC Comparison February 2026
NIVF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NIVF stands at 20.5K. In comparison, ALHC has a market cap of 4.1B. Regarding current trading prices, NIVF is priced at $0.84, while ALHC trades at $20.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NIVF currently has a P/E ratio of N/A, whereas ALHC's P/E ratio is -187.27. In terms of profitability, NIVF's ROE is +1.17%, compared to ALHC's ROE of -0.16%. Regarding short-term risk, NIVF is more volatile compared to ALHC. This indicates potentially higher risk in terms of short-term price fluctuations for NIVF.Check ALHC's competition here
NIVF vs OSCR Comparison February 2026
NIVF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NIVF stands at 20.5K. In comparison, OSCR has a market cap of 3.4B. Regarding current trading prices, NIVF is priced at $0.84, while OSCR trades at $13.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NIVF currently has a P/E ratio of N/A, whereas OSCR's P/E ratio is -7.83. In terms of profitability, NIVF's ROE is +1.17%, compared to OSCR's ROE of -0.39%. Regarding short-term risk, NIVF is more volatile compared to OSCR. This indicates potentially higher risk in terms of short-term price fluctuations for NIVF.Check OSCR's competition here
NIVF vs CLOV Comparison February 2026
NIVF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NIVF stands at 20.5K. In comparison, CLOV has a market cap of 1B. Regarding current trading prices, NIVF is priced at $0.84, while CLOV trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NIVF currently has a P/E ratio of N/A, whereas CLOV's P/E ratio is -18.36. In terms of profitability, NIVF's ROE is +1.17%, compared to CLOV's ROE of -0.17%. Regarding short-term risk, NIVF is more volatile compared to CLOV. This indicates potentially higher risk in terms of short-term price fluctuations for NIVF.Check CLOV's competition here
NIVF vs BHG Comparison February 2026
NIVF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NIVF stands at 20.5K. In comparison, BHG has a market cap of 130.5M. Regarding current trading prices, NIVF is priced at $0.84, while BHG trades at $16.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NIVF currently has a P/E ratio of N/A, whereas BHG's P/E ratio is -0.12. In terms of profitability, NIVF's ROE is +1.17%, compared to BHG's ROE of -0.65%. Regarding short-term risk, NIVF is less volatile compared to BHG. This indicates potentially lower risk in terms of short-term price fluctuations for NIVF.Check BHG's competition here
NIVF vs CABR Comparison February 2026
NIVF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NIVF stands at 20.5K. In comparison, CABR has a market cap of 12.1M. Regarding current trading prices, NIVF is priced at $0.84, while CABR trades at $0.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NIVF currently has a P/E ratio of N/A, whereas CABR's P/E ratio is N/A. In terms of profitability, NIVF's ROE is +1.17%, compared to CABR's ROE of N/A. Regarding short-term risk, NIVF is more volatile compared to CABR. This indicates potentially higher risk in terms of short-term price fluctuations for NIVF.Check CABR's competition here
NIVF vs BMGL Comparison February 2026
NIVF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NIVF stands at 20.5K. In comparison, BMGL has a market cap of 12M. Regarding current trading prices, NIVF is priced at $0.84, while BMGL trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NIVF currently has a P/E ratio of N/A, whereas BMGL's P/E ratio is -1.21. In terms of profitability, NIVF's ROE is +1.17%, compared to BMGL's ROE of -1.95%. Regarding short-term risk, NIVF is more volatile compared to BMGL. This indicates potentially higher risk in terms of short-term price fluctuations for NIVF.Check BMGL's competition here
NIVF vs MRAI Comparison February 2026
NIVF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NIVF stands at 20.5K. In comparison, MRAI has a market cap of 7M. Regarding current trading prices, NIVF is priced at $0.84, while MRAI trades at $0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NIVF currently has a P/E ratio of N/A, whereas MRAI's P/E ratio is -0.16. In terms of profitability, NIVF's ROE is +1.17%, compared to MRAI's ROE of +0.39%. Regarding short-term risk, NIVF is less volatile compared to MRAI. This indicates potentially lower risk in terms of short-term price fluctuations for NIVF.Check MRAI's competition here
NIVF vs GTS Comparison February 2026
NIVF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NIVF stands at 20.5K. In comparison, GTS has a market cap of 0. Regarding current trading prices, NIVF is priced at $0.84, while GTS trades at $35.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NIVF currently has a P/E ratio of N/A, whereas GTS's P/E ratio is 10.41. In terms of profitability, NIVF's ROE is +1.17%, compared to GTS's ROE of +0.07%. Regarding short-term risk, NIVF is more volatile compared to GTS. This indicates potentially higher risk in terms of short-term price fluctuations for NIVF.Check GTS's competition here
NIVF vs MGLN Comparison February 2026
NIVF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NIVF stands at 20.5K. In comparison, MGLN has a market cap of 0. Regarding current trading prices, NIVF is priced at $0.84, while MGLN trades at $94.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NIVF currently has a P/E ratio of N/A, whereas MGLN's P/E ratio is 8.49. In terms of profitability, NIVF's ROE is +1.17%, compared to MGLN's ROE of +0.00%. Regarding short-term risk, NIVF is more volatile compared to MGLN. This indicates potentially higher risk in terms of short-term price fluctuations for NIVF.Check MGLN's competition here